

PCV13 Schedules

MMWR Morbidity and Mortality Weekly Report

TABLE 1. Underlying medical conditions that are indications for pneumococcal vaccination among children, by risk group—Advisory Committee on Immunization Practices (ACIP), United States, 2010

Risk group	Condition
Immunocompetent children	Chronic heart disease* Chronic lung disease† Diabetes mellitus Cerebrospinal fluid leaks Cochlear implant
Children with functional or anatomic asplenia	Sickle cell disease and other hemoglobinopathies Congenital or acquired asplenia, or splenic dysfunction
Children with immunocompromising conditions	HIV infection Chronic renal failure and nephrotic syndrome Diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, and Hodgkin disease; or solid organ transplantation Congenital immunodeficiency‡

* Particularly cyanotic congenital heart disease and cardiac failure.

† Including asthma if treated with prolonged high-dose oral corticosteroids.

‡ Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).

TABLE 2. Recommended routine vaccination schedule for 13-valent pneumococcal conjugate vaccine (PCV13) among infants and children who have not received previous doses of 7-valent vaccine (PCV7) or PCV13, by age at first dose — Advisory Committee on Immunization Practices (ACIP), United States, 2010

Age at first dose (mos)	Primary PCV13 series*	PCV13 booster dose†
2–6	3 doses	1 dose at age 12–15 mos
7–11	2 doses	1 dose at age 12–15 mos
12–23	2 doses	—
24–59 (Healthy children)	1 dose	—
24–71 (Children with certain chronic diseases or immunocompromising conditions‡)	2 doses	—

* Minimum interval between doses is 8 weeks except for children vaccinated at age <12 months for whom minimum interval between doses is 4 weeks. Minimum age for administration of first dose is 6 weeks.

† Given at least 8 weeks after the previous dose.

‡ For complete list of conditions, see Table 1.

TABLE 3. Recommended transition schedule from 7-valent pneumococcal conjugate vaccine (PCV7) to 13-valent vaccine (PCV13) vaccination among infants and children, according to number of previous PCV7 doses received — Advisory Committee on Immunization Practices (ACIP), United States, 2010

Infant series			Booster dose	Supplemental PCV13 dose
2 mos	4 mos	6 mos	≥12 mos*	14–59 mos†
PCV7	PCV13	PCV13	PCV13	—
PCV7	PCV7	PCV13	PCV13	—
PCV7	PCV7	PCV7	PCV13	—
PCV7	PCV7	PCV7	PCV7	PCV13

* No additional PCV13 doses are indicated for children age 12–23 months who have received 2 or 3 doses of PCV before age 12 months and at least 1 dose of PCV13 at age ≥12 months.

† For children with underlying medical conditions (see Table 1), a single supplemental PCV13 dose is recommended through age 71 months.